REGULATORY, PRESS RELEASE

November 15th, 2019

RLS Global AB
Interim Report Q3, 2019

July 1st – September 30th

  • Net sales amounted to SEK 0.2 million (1.0)
  • Earnings before interest and taxes (EBIT) amounted to SEK -6,1 million (-4,9)
  • Earnings per share before dilution at SEK -0,11 (-0,08)
  • Cash flow from operating activities amounted to SEK -7,4 million (-5,8)
  • Liquid assets at the end of the period SEK 53,7 million (28,4)
  • Equity ratio was 90 percent (87)

January 1st – September 30th

  • Net sales amounted to SEK 1 million (1,5)
  • Earnings before interest and taxes (EBIT) amounted to SEK -17,8 million (-15,9)
  • Earnings per share before dilution at SEK -0,30 (-0,27)
  • Cash flow from operating activities amounted to SEK -19,2 million (-16,6)
  • Liquid assets at the end of the period SEK 53,7 million (28,4)
  • Equity ratio was 90 percent (87)

Summary of events during third quarter

  • ChloraSolv registration is now filed for Australia
  • A product specialist joined in August and will drive the ChloraSolv commercialization for the Swedish Market
  • An Extra General Meeting was held on August 19
  • A directed share issue in September generated approx. SEK 50 million in new funding

Summary of events after third quarter

  • The pre-RFD application to FDA in USA has been submitted
  • A new cooperation agreement has been signed with RISE regarding new additional
    pre-clinical tests
  • An evaluation of the current Business strategy for the Dental portfolio has been initiated
  • RLS is aiming to be ready for a MDR audit by end of the year
  • Our distributor OneMed has signed an agreement with five municipalitie

Trading place and certified advisor

RLS Global’s shares has been listed on the Nasdaq First North since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Erik Penser Bank, telephone +46 8 463 83 00, Email: certifiedadviser@penser.se.

During the period 2012 – 2017, the company was listed on Aktietorget.

Contact information

Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

Publication

RLS Global AB (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation. The information was submitted for publication through the agency of the above contact person, at 08:30 CET on August 15th, 2019.

About RLS Global For more than 20 years, RLS Global has worked with Oral Care specialists, pioneering new therapies for Oral Care and their patients. We are now taking another major step toward easier and more effective care within Wound Care. We will continue to work with Health care Professionals to ensure to develop a treatment that further helps deliver the best care for each patient. The method is clinically proven and saves the patient a lot of suffering. Our focus is on caring for the patients, developing efficient and safe products that offer gentle treatment methods. We’re proud to provide Minimally Invasive Therapy which provides Quality of Life for patients worldwide.